Mice homozygous for thegus" allele lack@-glucuronidase activity and provide a useful model for human Mucopolysaccharidosis type VI1 (MPS VII), also known as Sly syndrome. Bone marrow (BM) transplantation was shown to correct the metabolic defect and to increase the life span of diseased animals. We have used this murine model in a preclinical study aimed at evaluating whether the techniques currently available for gene transfer into large mammalian and human BM cells will provide efficient enzyme replacement therapy in MPS patients. Autologous BM was transplanted into deficient mice after retrovirus-mediated transfer of the human @-glucuronidase cDNA. Conditioning YSOSOMAL storage diseases form a group of more L than 30 inborn errors of the metabolism characterized by the accumulation of undegraded catabolites in lysosomes. Most of these diseases are due to a single enzyme defect interrupting the degradation of proteoglycans, as in mucopolysaccharidosis (MPS), or the degradation of proteolipids, as in sphingomyelinosis. The discovery of a secretory pathway for lysosomal enzymes and the demonstration of their capture by distant cells have provided a rationale for enzyme replacement therapy in certain lysosomal diseases.'" Enzyme replacement therapy is performed with some success by infusing a purified preparation of macrophage-targeted enzyme in Gaucher disease, one of the most prevalent lysosomal disorder^.^ However, this approach is limited because of the cost of the purification process, and it is not available for other lysosomal diseases. Transplantation of allogeneic bone marrow (BM) cells, providing a source for replacement enzyme, has been beneficial in certain forms of animal5-' and human9.10 lysosomal disorders. However, this procedure has a high morbidity and mortality rate and is restricted to patients with matched donors, offering no satisfactory treatment for many patients.
engineered tissue may provide a cure for the deficiency. Long-term expression of foreign genes has now been reported after gene transfer into various tissues, including skin fibroblasts, skeletal muscle, and liver, although the best documented gene transfer procedure involved hematopoietic cells.L1 Success was recently obtained using retrovirus-mediated gene transfer into hematopoietic BM stem cells in dog^,'^,'^ cats,I4 monkeys,I5-" and humans'' (C. Bordignon, personal communication, September 1992). Protocols using retrovirus-mediated gene transfer into BM cells have now been approved for the treatment of adenosine-deaminase-deficient patients." However, in contrast with the observations made in the mouse, gene transfer into BM stem cells of large mammals and humans appears relatively inefficient, because only a few percent of genetically modified cells persist in the blood after several months. Before such an approach can be proposed for enzyme replacement therapy in lysosomal disorders, it needs to be documented whether a substantial reduction of lysosomal storage can be obtained with low numbers of genetically modified hematopoietic cells. This issue can be examined in the case of MPS because excellent animal models are available for these diseases.
Mice homozygous for the gusmps'mps allele have a complete @-glucuronidase deficiency and share many clinical features with human MPS type VII, including facial dysmorphism, growth retardation, skeletal deformities, splenomegaly, and a shortened life span." Birkenmeier et als have shown that the transplantation of nondeficient BM corrects the metabolic defect, clears stored material from lysosomes, and increases mutant mouse lifespan. We have used sublethally irradiated recipient MPS VI1 animals to test whether the presence of low numbers of genetically modified hematopoietic cells will have a similar effect. The human P-glucuronidase cDNA was introduced into MPS VI1 BM cells by retrovirus-mediated gene transfer, and cells were then reinfused in MPS VI1 recipients. Because of the low conditioning regimen, engraftment of donor cells was inefficient, and the hematopoietic tissues of recipient mice killed between days 40 and 145 after gene transfer contained only a few percent of genetically modified cells. Nevertheless, @-glucuronidase activity was detected in various organs, including the brain, and the spleen and liver showed a 
MATERIALS AND METHODS
Animals. Mice carrying the guyps allele (B6.C-H-2'"lByBirgusmp'+) were obtained from E. Birkenmeier (The Jackson Laboratory, Bar Harbor, ME). Homozygous guyps/guYp 0-glucuronidase mutants were produced and identified before weaning by the absence of 0-glucuronidase activity in cell extracts prepared from tail samples.
Vector and cells. The construction of the GLU-3 retrovirus vector and the isolation of high virus producer GCRE clones have been described previously.21 Amphotropic +GRIP producers were similarly isolated. Both vector-producer cell clones transferred more than one vector copy to NIH/3T3 target cells. In these cells, RNase protection analysis indicated that the internal phospho-glycerate kinase promotd2 inserted in the GLU-3 vector controls the transcription of the human 0-glucuronidase c D N A~~ (data not shown). Infection of MPS VI1 mouse fibroblasts with the GLU-3 vector led to the in situ detection of 0-glucuronidase activity in more than 90% of target cells. One hundred twenty to 150 U of @-glucuronidase were secreted in the supernatant of IO6 infected cells in 24 hours.
BM cells were harvested from donor mice 5 days after intravenous injection of 100 mg/kg 5-fluOrOuracil. They were cocultivated for 48 hours with GLU-3 producer cells in Dulbecco's modified Eagle's medium (DMEM) supplemented with 15% fetal calf serum, 200 U/mL recombinant interleukin-3 (IL-3), 200 U/mL recombinant IL-6, 50 U/mL recombinant IL-la (British Biotechnologies, Oxon, UK), and 4 pg/mL Polybrene (Sigma, St Louis, MO). BM cells were collected after cocultivation, centrifuged, and 3 X lo6 to 20 X lo6 cells were resuspended in 0.2 mL of serum-free medium for retro-orbital intravenous (IV) injection in syngeneic recipients. Conditioning of recipients was performed by a single 4.5 C y total body irradiation (TBI) delivered from a 13'Cs irradiator 4 hours before transplantation.
DNA analysis. Polymerase chain reactions (PCR) on blood and spleen cell samples were performed as previously described." For Southern blot analysis, high molecular weight DNAs were prepared from spleen cells, digested with Kpn I, run on 1% agarose gels, transferred to nylon membranes, and probed with the 2,190-bp EcoRI fragment from plasmid HuGP13;' which corresponds to the human 0-glucuronidase cDNA. High specific activity probes were obtained by random primer extension in the presence of four 32P-labeled deoxynucleotides. After stringent hybridization and washing, membranes were scanned with Phospho-Imager (Molecular Dynamics, Sunnyvale, CA) and autoradiographed. The proportion of female donor and male recipient cells was determined on Kpn Idigested DNAs from three animals. Samples were processed in parallel with known mixtures of male and female DNAs, and membranes were hybridized with 32P-dCTP-labeled mouse Y-chromosome-specific probe (EcoRV-Sal I 1-kb fragment from plasmid PY224). After stringent washing, membranes were autoradiographed and films were scanned with a densitometer (Hoeffer Scientific Instruments, San Francisco, CA). Endogenous murine p-glucuronidase sequences were shown by a human 0-glucuronidase probe to provide an internal reference for DNA amounts.
Biochemical analyses. To prepare cell extracts, organ fragments were lysed in 0.02 mmol/L Tris, pH 7.5,75 mmol/L NaCl at 4"C, centrifuged to remove nuclei, and resuspended in the same buffer at a protein concentration of 0. I5 mg/mL. @-Glucuronidase Gene transfer into BM cells. activity was measured by fluorometry using 4-methylumbelliferyl-P-D-glucuronide as a sub~trate.'~ Glycosaminoglycan levels were measured as described.26 Briefly, 1 to 2 pL of urine in microtitration wells was added to 300 pL of 20 pmol/L dimethyl-methylene blue at pH 3.5. Absorbance was then measured at 570 nm and compared with standard value.
Histologic analysis. In situ 0-glucuronidase activity was shown on paraformaldehyde-fixed 10-pm frozen sections by overnight incubation at 4°C with naphtol-AS-BI 0-D-glucuronide and pararosaniline hydr~chloride.~' Spleen, liver, lung, kidney, muscle, brain, cornea, and joints from all treated animals and three age-matched untreated mutants or normal mice were examined by light microscopy. Electron microscopy was performed on the liver of mouse number 4.
Helper virus assay. All treated animals were examined for the presence of replication-competent retrovirus. Sera and supernatants from spleen cell cultures were used to infect target fibroblasts. Cells were grown for 2 weeks to allow virus amplification and supernatants were tested by a virus mobilization assay that can detect one replication-competent ecotropic or amphotropic particle per milliliter.28 RESULTS P-Glucuronidase-deficient BM cells were obtained from 6-to 8-week-old MPS VI1 mice that received 100 mg/kg of 5-fluorouracil 5 days before. Transfer of the human P-glucuronidase cDNA was performed during a 2-day cocultivation with the GLU-3 retroviral vector producer cells, and 3 X lo6 to 20 X lo6 cocultivated BM cells were transplanted into MPS VI1 animals (Table 1) . Recipient animals received a 4.5 Gy TBI immediately before injection. As a result of this nonlethal irradiation, the repopulating BM cell population was expected to be a mixture from both endogenous and exogenous origin. The ratio of donor to recipient cells was measured by Southern blot in male recipients of female BM cells. We could only perform this type of engraftment in three MPS VI1 mice because of the limited availability of mutant animals (mice 3,4, and 7). The percentage of donor cells in these animals was less than 5%.
The presence of GLU-3 vector DNA in circulating blood cells was examined by PCR at day 30 after transplantation (not shown). Ten of 12 animals were positive and were killed between days 40 and 60 (mice 1 through 5) or be- For personal use only. on October 22, 2017. by guest www.bloodjournal.org From tween days 123 and 145 (mice 6 through IO). High molecular weight DNA was prepared from the spleens of killed animals and was shown to contain the GLU-3 provirus by PCR (not shown). Southern blot analysis was performed to estimate the percentage of cells containing GLU-3 vector copy in their genome (Fig I) . The human &glucuronidase probe was labeled with four nucleotides to allow the detection of 0.05 vector genome copy per cell in control DNA. After digestion with Kpn I, an internal 2.45-kb vector fragment was detected by Southern blot in the BM and spleen DNAs from 6 of the IO analyzed mice. Comparison with copy number controls and normalization according to the amount of DNA indicated that the average vector copy number was 0.05 in the spleen of mice 8,9. and IO, and 0.0 I to 0.02 in the spleen of mice I , 3, and 7. Considering that the integration of several vector genomes in the same cell was unlikely in this experiment, we estimated the percentage of positive cells in the spleen in the range of 5% for mice 8,9, and IO. and 1% for mice 1.3, and 7 ( Fig I) . Mice 2,4,5, and 6, which were positive by PCR and negative by Southern blot analysis, must have less than 1% positive cells in the spleen.
Only background &glucuronidase activity could be measured in tissue extracts of MPS VI1 mutant mice (Table 2) . and the enzyme activity was not detectable on tissue sections (not shown). Despite the low number of hematopoietic cells that contained 0-glucuronidase vector in their genome, (?-glucuronidase activity was present in the spleen, BM, liver, and lung of all treated mutant animals. Enzyme
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MARECHAL ET AL levels varied among different tissues. Highest levels were found in spleen extracts. with a range of 0.2% to 19% of the level in heterozygotes. ,f3-Glucuronidase-positive cells were predominantly located in the white pulp of the spleen (Fig  2) . In BM, @-glucuronidase activity represented 0.22% to 4% of the level in heterozygote, and was mostly observed in myelo-monocytic cells (not shown). In the liver, we measured 0.4% to 2% of the activity level in heterozygote. Positive cells lined sinusoid capillaries and were likely to be Kiipffer cells (Fig 2) . Low enzyme activity was measured in lung extracts (0.3% to 0.5% of the level in heterozyte), whereas a few positive cells were observed on lung sections (not shown). @-Glucuronidase activity was detected on brain sections from mice 9 (Fig 2) and IO. Significant enzyme level was measured in a brain extract from mouse 9, representing 2.9% of the level in heterozygotes. Most lymph node samples showed very low enzyme activity. The levels of &glucuronidase activity varied among different animals. Animals 8,9, and IO with 5% genetically modified hematopoietic cells showed the highest activity levels. However, animals in which vector copy could be detected only by PCR also had significant enzyme activity in some tissues (see mouse 4, spleen, BM, and liver: mouse 6, spleen). These results indicated that the human &glucuronidase cDNA inserted in the GLU-3 vector was efficiently expressed from the PGK promoter in genetically modified hematopoietic cells for more than 140 days.
Because the degradative pathways of dermatan, heparan, and chondroitin sulfates are interrupted in the absence of For personal use only. on October 22, 2017. by guest www.bloodjournal.org From This single measurement suggested that the stored pool of undegradated catabolites had been reduced in treated mutant mice. The symptomatology of P-glucuronidase-deficient MPS VI1 mutants includes facial dysmorphy, bone deformities, corneal clouding, and deafness. Mortality at 200 days is greater than 80%. No obvious improvement ofthese clinical symptoms was noticed in treated animals. However, mice 6 through 10 appeared more active than their untreated mutant littermates when they were killed at the age of 150 to 196 days. In diseased animals, characteristic MPS features can be recognized easily on tissue sections. A huge distension of lysosomes responsible for a complete disorganization of the tissue structure was obvious in the liver of untreated animals killed at day 68 (Fig 3A) or later. Electron micrographs showed that lysosomal distension not only affected nonparenchymal cells, but also involved hepatocytes (Fig 4A) . Histologic examination ofthe liver ofall 10 treated animals showed a drastic reduction of lysosomal distension, which in most cases led to a complete normalization of the tissue architecture (Fig 3B and C) . This observation was confirmed by electron microscopy of liver thin sections, which showed a disappearance of lysosomal distension in both sinusoid lining cells and hepatocytes (Fig 4B) . In the spleen of untreated mice, abnormalities were predominantly located in the white pulp. Large white areas due to the presence of severely distended cells disorganized the tissue architecture (Fig 5A) . In all 10 treated animals, the histology of the spleen was fully normalized and indistinguishable from those of unaffected heterozygotes (Fig 5B and C) . We concluded from these observations that low enzymatic activities measured in the liver and spleen oftreated animals were sufficient for a complete disappearance of lysosomal storage lesions in these organs. Despite the presence of /%glucuronidase enzyme activity in the brain of two animals, no improvement of the cell morphology could be shown in these tissues. Similarly, lysosomal distension persisted in joint cartilage.
DISCUSS ION
The transplantation of BM from an HLA-matched sibling or unrelated donor is currently the only satisfactory treatment for MPS. Because of the lack of a matched donor, it is performed in less than one-half of patients, and it is still associated with a high morbidity and mortality. In a mouse model for MPS VII, we show here that a phenotypic correction reminiscent of the observations previously made after syngeneic BM transplantation* can be obtained by gene transfer into a low number of hematopoietic cells. Therefore, although the currently available procedures for longterm gene transfer into the BM cells of large mammal^'^-'^ and humans involved only low numbers of cells, our results suggest that this approach can be beneficial in MPS patients, especially when allogenic BM transplantation is not feasible.
The engraftment of autologous BM is highly dependent on the conditioning regimen applied to the recipient. In the mouse, the proportion of donor cells varies as a function of TBI dose and fra~tionation.~~ According to published data, the transplantation of 7 X lo6 to IO' cells into 4.5 Gy irradiated recipient was expected to give rise to 30% to 60% donor By detecting Y-specific sequences on Southern blot, we could measure donor engraftment in three mutant male animals that received syngeneic female BM cells. After a single 4.5 Gy TBI, less than 5% of donor cells were detected in animals transplanted with 3 X lo6 to I .2 X lo7 cells. This inefficient engraftment suggests that the repopulating capability of donor BM cells has decreased during the 2 days of cocultivation with retrovirus vectorproducing fibroblasts. This implies that high numbers of cells are required for efficient engraftment of autologous BM after in vitro cultivation for gene transfer. However, it is also possible that the capacity of BM cells to repopulate recipient animals is affected in lysosomal diseases.
In MPS VI1 mice, &glucuronidase activity is absent in tissue extracts. Despite the low number of genetically modified cells in their tissues, all recipient animals showed 8-glucuronidase activity in variousargans. Either significant level of enzyme activity in cell extracts or positively stained cells after in situ revelation of 8-glucuronidase could be detected in the spleen, BM, liver, and lung of all treated animals. Except in two recipients, enzyme activity in lymph nodes was not significant, suggesting either that myeloid donor BM stem cell engrafted in most animals or that expression was low in this tissue. The highest enzyme activity levels were found in mice that received the highest numbers of donor cells and that contained the highest numbers ofgenetically modified cells in their hematopoietic tissues (Table 2 , spleen and BM of mice 8 and 9). However, a relationship between the percentage of genetically modified cells and the enzyme activity levels was inconsistently observed ( Table 2 , compare the activity in the liver of mice 4 and IO), and no significant correlation existed. Enzyme activity levels were equivalent or even higher in animals transplanted for more than 5 months. This suggests that gene transfer was efficient enough to target long-term repopulating stem cells. It also indicates that the transcriptional activity of the internal mouse PGK promoter inserted in the GLU-3 vector was conserved for several months in the hematopoietic tissue. Antibodies directed against the human &glucuronidase were searched for in the serum of sublethally irradiated recipient mice by Western blotting using purified enzyme and were found only in mice 5 and 10. Enzyme activity was detected in the spleen, BM, liver, and lung of all treated animals and in the brain of two of them. The correction of lysosomal storage was easily recognized on spleen and liver sections. In 8 of 10 animals, the histologic appearance of liver and spleen were indistinguishable from healthy heterozygous siblings. Residual lysosomal distension persisted in two mice (2 and 6) that harbored very low numbers of genetically modified cells.
Exchanging of &glucuronidase between normal and deficient cells has been extensively studied." We previously observed in vitro uptake by fibroblasts and macrophages of the For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From suggested either that enzyme levels in hepatocytes were too low for in situ detection or that scavenging of extracellular glycosaminoglycans by Kupffer cells is beneficial for surrounding hepatocytes."
Although treated mice killed at the age of 150 to I96 days appeared more active than untreated mutant littermates, we observed no improvement of the macroscopic abnormalities of MPS VII, including skeletal deformities and deafness. The brain and cartilage tissues, which are already damaged before weaning:2 still showed severe lysosomal distension. We assume that genetic complementation has to be performed very early in life, before the onset of severe lesions, to prevent or reduce brain and skeletal damage. However, we cannot exclude that enzyme levels were too low in our experiment to allow phenotypic correction in these tissues. Very long-term observation of treated animals, together with experiments performed in the available dog and cat models for MPS, will be useful to assess the benefits that may be expected from gene transfer into human MPS patients.
The reversal of pathology in the liver and spleen of MPS VI1 mice has been described in two recent reports. Using a retrovirus vector expressing the rat @-glucuronidase cDNA from a thymidine kinase promoter, Wolfe et al" obtained a phenotypic correction in two animals after gene transfer into BM cells. Although a lethal irradiation of recipient mice led to the efficient engraftment of genetically modified cells, the levels of &glucuronidase measured in tissue were only slightly higher than in our present experiments. We show here, using a retrovirus vector with an internal PGK promoter, that a similar therapeutic effect can be obtained with small numbers of genetically modified hematopoietic cells, which is a situation more relevant to future human trials. Using a different approach, we have also shown that genetically modified autologous fibroblasts implanted in MPS VI1 mice within organoids excrete /3-glucuronidase for more than 5 months and induce a disappearance of lysosomal storage in the liver and spleen."
